Phosphodiesterase (PDE) inhibitors in the treatment of lower urinary tract dysfunction.
about
Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasiaExpected Next-Generation Drugs Under Development in Relation to Voiding SymptomsCyclic nucleotide phosphodiesterases: important signaling modulators and therapeutic targets.Control of urinary drainage and voiding.Testosterone regulates smooth muscle contractile pathways in the rat prostate: emphasis on PDE5 signaling.Selective inhibition of phosphodiesterase 1 relaxes urinary bladder smooth muscle: role for ryanodine receptor-mediated BK channel activation.PDE5-Is for the Treatment of Concomitant ED and LUTS/BPH.An animal study to compare the degree of the suppressive effects on the afferent pathways of micturition between tamsulosin and sildenafilClinical and molecular genetics of the phosphodiesterases (PDEs).Tadalafil: in the treatment of signs and symptoms of benign prostatic hyperplasia with or without erectile dysfunction.Tadalafil: a phosphodiesterase-5 inhibitor for benign prostatic hyperplasia.The role of phosphodiesterases in bladder pathophysiology.Management of benign prostatic hyperplasia: role of phosphodiesterase-5 inhibitors.Impact of cardiovascular risk factors and related comorbid conditions and medical therapy reported at baseline on the treatment response to tadalafil 5 mg once-daily in men with lower urinary tract symptoms associated with benign prostatic hyperplasProtective effect of tadalafil on the functional and structural changes of the rat ventral prostate caused by chronic pelvic ischemia.Clinical pharmacology of functional disorders of the urogenital system.Phosphodiesterase type 5 and cancers: progress and challenges.Urethral dysfunction due to alloxan-induced diabetes. Urodynamic evaluation and action of sildenafil citrate.Phosphodiesterase type 5 (PDE5) is co-localized with key proteins of the nitric oxide/cyclic GMP signaling in the human prostate.
P2860
Q24199135-E331DD49-AD89-42A3-A484-E06F84F75980Q33871856-82293B0B-2436-4C78-9342-C2467A235552Q34765802-8C3159F4-505C-4216-8775-603D5F3785FAQ35144401-16665929-16EC-46E3-854B-E6389F62A76FQ35924409-18A6916C-E13B-4286-AC97-F4814122CB06Q36382456-B58AD8BB-807F-4EFA-B68B-61350E719939Q37025381-5EBB6B40-1716-4264-8E00-9A1092FA293CQ37410152-BA7EDBA9-F1EE-47A6-BB51-8811248AFFE6Q37657841-29042C76-5844-4934-B613-82C2DD1E120BQ38047228-966196D3-0963-4AC2-A6A5-BDA185942E83Q38093143-801D4C52-3773-4A4F-BDC0-F142FD73FDF8Q38106628-2AC546D3-DE1A-47D1-8EF0-84C50A6AB87EQ38210468-1E535710-325E-4A4D-9700-5246EF83A602Q40615541-79BA77ED-90E5-4C80-B1E2-5E6761880FABQ42200788-6D812E0A-3EF5-4542-AAD1-5A033338F4F2Q42876778-0B0A21EE-E473-4609-ADED-5DE2EA38FECEQ47171803-D5B5685E-E7CC-47E6-987B-FD334C997031Q47880143-A67E2377-1D20-4EB6-8E09-FEB3543E5E55Q54445165-6F0D8417-5734-4C7D-821E-025186F18CDD
P2860
Phosphodiesterase (PDE) inhibitors in the treatment of lower urinary tract dysfunction.
description
2011 nî lūn-bûn
@nan
2011 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Phosphodiesterase (PDE) inhibitors in the treatment of lower urinary tract dysfunction.
@ast
Phosphodiesterase (PDE) inhibitors in the treatment of lower urinary tract dysfunction.
@en
type
label
Phosphodiesterase (PDE) inhibitors in the treatment of lower urinary tract dysfunction.
@ast
Phosphodiesterase (PDE) inhibitors in the treatment of lower urinary tract dysfunction.
@en
prefLabel
Phosphodiesterase (PDE) inhibitors in the treatment of lower urinary tract dysfunction.
@ast
Phosphodiesterase (PDE) inhibitors in the treatment of lower urinary tract dysfunction.
@en
P2860
P1476
Phosphodiesterase (PDE) inhibitors in the treatment of lower urinary tract dysfunction.
@en
P2093
Matthias Oelke
Stefan Uckert
P2860
P304
P356
10.1111/J.1365-2125.2010.03828.X
P407
P577
2011-08-01T00:00:00Z